CAS 1402820-62-5

General Information

Derived from needles of yew trees, cabazitaxel is prescribed for the treatment of patients with hormone-refractory prostate cancer (HRPC) that has spread to other parts of the body and was previously treated with a docetaxel-containing treatment regimen. It is used in combination with prednisone. HRPC is a prostate cancer that has become unresponsive to hormonal manipulation.Cabazitaxel is administered intravenously.

About the API

Systematic name (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate – propan-2-one (1
Trade name(s) Jevtana
Technology Synthetic
Molecular Formula C45H57NO14.C3H6O
Molecular Weight 894.01 g/mol
Physical properties White to almost-white powder
Therapeutic category Oncology
Available formulations Injectables
Regulations Canada DMF Flag Canada DMF CEP Flag CEP EU DMF Flag EU DMF US DMF Flag US DMF